Abstract
To compare user satisfaction and adverse events (AEs) with use of the 13.5 mg total content levonorgestrel intrauterine contraceptive system (LNG-IUS13.5mg) and a 30 μg ethinyl estradiol/3 mg drospirenone combined oral contraceptive (COC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
